The mechanism and progress of PARP inhibitors in the treatment of advanced breast cancer
10.3969/j.issn.1000-8179.2019.11.436
- VernacularTitle:PARP抑制剂治疗晚期乳腺癌的作用机制及相关研究进展
- Author:
Jing WU
1
;
Xiaohua ZENG
Author Information
1. 重庆大学附属肿瘤医院肿瘤转移与个体化诊治转化研究重庆市重点实验室(重庆市400030
- Keywords:
PARP inhibitor;
BRCA mutation;
breast cancer;
mechanism;
treatment progress
- From:
Chinese Journal of Clinical Oncology
2019;46(11):586-588
- CountryChina
- Language:Chinese
-
Abstract:
Poly ADP-ribose polymerase (PARP) inhibitors can block the repair of DNA single-strand breaks, and BRCA mutation can cause the loss of repair function of DNA double-strand damage in breast cancer cells. Therefore, PARP inhibitors are used to treat BRCA-mutant breast cancer by simultaneously blocking the repair of DNA single-strand breaks and DNA double-strand damage, which leads to the failure of DNA repair, resulting in the death of cancer cells. At present, a variety of PARP inhibitors have been developed that primarily inhibit PARP1 and PARP2 subtypes with high sensitivity and specificity. This review summarizes the mechanism of PARP inhibitors in the treatment of breast cancer with BRCA mutation, and states the progress of several reported PARP inhibitors used alone or in combination with commonly used chemotherapeutic agents for the treatment of advanced breast cancer.
